Viral Vector Manufacturing Market Report 2026

Viral Vector Manufacturing Market Overview

• Viral Vector Manufacturing market size has reached to $8.26 billion in 2025 • Expected to grow to $21.31 billion in 2030 at a compound annual growth rate (CAGR) of 21.1% • Growth Driver: Impact Of Rising Cancer And Infectious Diseases On The Viral Vector Manufacturing Market • Market Trend: Advanced Analytical Viral Vector Platform Propel Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the viral vector manufacturing market include: • Adeno-Associated Viral Vectors (Segmentation By Type) → Expected gain of $5.1 Billion • Lentiviral Vectors (Segmentation By Type) → Expected gain of $4.51 Billion • Adenoviral Vectors (Segmentation By Type) → Expected gain of $2.68 Billion

What Is Covered Under Viral Vector Manufacturing Market?

Viral vector manufacturing refers to producing viral vectors, tools that deliver genetic material into cells. A viral vector is a tool for gene transfer that can manipulate a particular cell type or tissue to express therapeutic genes. The main types of viral vector manufacturing are adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and others. Adenoviral vectors refer to double-stranded DNA vectors that are not enclosed. The various diseases covered are cancer, genetic disorders, infectious diseases, and others with various workflows such as upstream processing and downstream processing. The various applications used are gene and cell therapy development, vaccine development, biopharmaceutical and pharmaceutical discovery, and biomedical research used in research organizations, biotech and pharmaceutical companies, and others.

What Is The Viral Vector Manufacturing Market Growth Forecast?

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $21.31 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to growing demand for gene and cell therapies, advancements in viral vector technology, increased R&D investments, expansion of contract manufacturing organizations, rising adoption of personalized medicine. Major trends in the forecast period include gene therapy innovation, viral vector safety optimization, scalable manufacturing processes, regulatory compliance enhancement, advanced upstream and downstream processing.

What Is The Driver Of The Viral Vector Manufacturing Market?

The increase in the prevalence of cancer and infectious diseases is expected to propel the growth of the viral vector manufacturing market going forward. An infectious disease refers to a condition brought on by a virus or its toxic byproduct and spread to a susceptible host via contact with an infected person, animal, or item. Cancer refers to a broad range of illnesses that can develop in any organ or tissue of the body when aberrant cells grow out of control, cross their usual boundaries to invade neighboring organs, and spread to other organs. Tumor antigens, or proteins on tumor cells, are produced via viral vectors to elicit the body's anticancer immune response. In pre-clinical and clinical trials, viral vectors have served as vaccines against various infectious illnesses. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia the number of cancer cases diagnosed increased from 160,570 in 2022 to 164,694 in 2023, reflecting a notable rise over the year. This upward trend highlights the growing prevalence of cancer within the country. Furthermore, in August 2024, according to the data published by the UK Health Security Agency, a UK-based executive agency, in England, the UK Health Security Agency (UKHSA) reported 368 measles cases in 2023, marking a nearly sevenfold increase from the 53 cases reported in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Therefore, the increase in the prevalence of cancer and infectious diseases is driving the growth of the viral vector manufacturing industry.

How Will The Drivers Impact Growth In The Global Viral Vector Manufacturing Market?

• The Increasing R&D In Cell And Gene Therapy (High) – During the forecast period, the increasing r&d in cell and gene therapy is expected to become a key growth driver for the viral vector manufacturing market by 2030. The surge in research and development activities in cell and gene therapy directly increases demand for high -quality viral vectors used as gene delivery tools. As more therapeutic candidates move from discovery to preclinical and clinical stages, manufacturers must produce larger volumes of vectors under stringent quality standards. Each new therapy requires customized vector design, process optimization, and scalable production capabilities. This expands the need for specialized manufacturing infrastructure and technical expertise. Consequently, intensified r&d activity acts as a primary catalyst for sustained growth in viral vector manufacturing services. • The Increasing Number Of Clinical Trials Of Viral Vectors (High) – During the forecast period, the increasing number of clinical trials of viral vectors is expected to emerge as a major factor driving the expansion of the viral vector manufacturing market by 2030. A rising number of clinical trials involving viral vector-based therapies significantly boosts manufacturing requirements. Every clinical phase demands compliant production batches, validation runs, and consistent supply for multicenter trials. As programs advance from phase i to phase iii, vector volume requirements increase substantially. This progression drives both small-scale and large-scale manufacturing contracts, strengthening revenue streams for contract development and manufacturing organizations (cdmos). Therefore, expanding clinical pipelines directly translate into higher production demand and capacity expansion in this market. • The Availability Of Funding For Gene Therapy Development (Medium) – During the forecast period, the availability of funding for gene therapy development is expected to act as a key growth catalyst for the viral vector manufacturing market by 2030. Greater availability of public and private funding enables biotechnology firms to accelerate gene therapy development programs. Financial backing supports investment in vector design, process development, gmp manufacturing, and regulatory compliance. Well-funded companies are more likely to outsource or expand manufacturing partnerships to ensure timely clinical progression. Increased capital inflow also encourages facility expansion and technological upgrades within manufacturing organizations. As a result, strong funding availability fuels both innovation and production scale-up, driving overall market growth.

How Will The Restraints Impact Growth In The Global Viral Vector Manufacturing Market?

• Disadvantage of Having a Short Life (Medium) – During the forecast period, the some viral vectors have limited stability and a short shelf life, which complicates storage, transportation, and long-term inventory management. This increases the risk of product loss and wastage, especially during global distribution. Manufacturers must invest in advanced cold-chain logistics and stabilization technologies, raising operational costs. Limited stability also restricts flexible production scheduling and batch holding capacity. As a result, short product lifespan can slow commercialization and reduce manufacturing efficiency. • The High Cost of Gene-Based Medical Therapies (High) – During the forecast period, the gene-based therapies are expensive due to complex development processes, stringent regulatory requirements, and highly specialized manufacturing systems. The high end-product price limits patient accessibility and reimbursement approvals in many regions. When demand is constrained by affordability concerns, large-scale manufacturing expansion becomes commercially risky. Additionally, smaller biotech firms may struggle to fund production at required gmp standards. This cost burden acts as a barrier to rapid market penetration and capacity scaling. • Challenges in Viral Vector Manufacturing Capacity (High) – During the forecast period, the viral vector production is technically complex, requiring advanced bioprocessing infrastructure, skilled personnel, and strict quality control systems. Global manufacturing capacity often lags behind growing clinical demand, leading to supply bottlenecks. Limited availability of gmp-certified facilities can delay clinical trials and product launches. Capacity constraints also increase contract manufacturing costs due to high demand and limited supply. These operational limitations restrict the pace at which the market can expand.

Key Players In The Global Viral Vector Manufacturing Market

Major companies operating in the viral vector manufacturing market are Sanofi S.A., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV

Global Viral Vector Manufacturing Market Trends and Insights

Major companies operating in the viral vector manufacturing market are focusing on developing advanced products, such as viral vector platforms specifically designed for viral vector production and manufacturing. Viral vector platforms are comprehensive systems tailored to efficiently produce and process viral vectors for applications such as gene therapy and vaccine development. For instance, in May 2023, AGC Biologics, a US-based global biopharmaceutical contract development and manufacturing organization (CDMO), launched the BravoAAV and ProntoLVV platforms, designed to offer flexible and accelerated vector development and manufacturing for cell and gene therapy programs. These platforms, designed for flexible and accelerated vector development and manufacturing in cell and gene therapy programs, offer GMP product delivery in nine months, supported by a global regulatory and supply network and in-house plasmid DNA services. With custom processes, templated material approaches, and prequalified analytical methods, these platforms are significant contributors to the viral vector manufacturing market's projected growth, reaching $5.5 billion by 2035, by meeting the increasing demand for efficient development and delivery of life-changing gene therapies and vaccines.

What Are Latest Mergers And Acquisitions In The Viral Vector Manufacturing Market?

In January 2024, Oxford Biomedica Plc, a UK-based biotechnology company, acquired ABL Europe from Institut Mérieux, for $16 million (15 million euros). Through this acquisition, Oxford Biomedica will the production facilities in Lyon and Strasbourg, France, and will be able to offer multi-viral vector CDMO capabilities, boasting six manufacturing sites in the EU, U.S., and U.K. ABL Europe is a France-based contract development and manufacturing organization (CDMO) that provides viral vector manufacturing services.

What Defines the Viral Vector Manufacturing Market?

The viral vector manufacturing market includes revenues earned by entities through the production, packaging, and labeling of viral vector vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Vector Manufacturing Market Report 2026?

The viral vector manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.